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Abstract 
Objectives: To evaluate the association between blood pressure (BP) measurements and 
adverse outcomes in women with pre-eclampsia. 
Study design: A prospective cohort study of women with pre-eclampsia admitted to three 
South African tertiary facilities. BP was measured using the CRADLE Vital Signs Alert (VSA), 
incorporated with a traffic light early warning system; green: systolic BP<140mmHg and 
diastolic BP<90mmHg, yellow: systolic BP140–159 and/or diastolic BP90–109mmHg (but 
neither is above the upper threshold), red: systolic BP≥160mmHg and/or diastolic 
BP≥110mmHg.  
Main outcome measures: maternal: death, eclampsia, stroke, kidney injury; process 
measures: magnesium sulfate use, Critical Care Unit (CCU) admission; perinatal: stillbirth, 
neonatal death, preterm delivery. 
Results: Of 1547 women with pre-eclampsia (including 42 twin pregnancies), 33.0% of 
women triggered a red light on admission and 78.6% at their highest BP. Severe 
hypertension and adverse outcomes were common across yellow and red categories. 
Comparing admission red to yellow lights, there was a significant increase in kidney injury 
(OR 1.74, CI 1.31-2.33, trend test p=0.003), magnesium sulfate use (OR 3.40, CI 2.24-5.18, 
p<0.001) and CCU admission (OR 1.50, CI 1.18-1.91, p<0.001), but not for maternal death, 
eclampsia, extended perinatal death or preterm delivery.  
Conclusion: The CRADLE VSA, with integrated traffic light early warning system, can identify 
women who are hypertensive, at increased risk of severe pre-eclampsia complications and in 
need of escalation of care. Women who triggered a red light were at increased risk of kidney 
injury, magnesium sulfate use and CCU admission.  
 
Keywords: Pre-eclampsia; hypertension; blood pressure; early warning system  
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Introduction 
Pre-eclampsia affects 3-5% of pregnancies and is a leading cause of maternal and perinatal 
mortality and severe morbidity globally.1, 2 In high-income countries, maternal mortality 
from pre-eclampsia is now rare; this is a result of prompt action following diagnosis 
facilitated by blood pressure (BP) and urinary dipstick proteinuria measurement.3 In low- 
and middle-income countries (LMIC) settings, where 99% of all maternal deaths occur, 
healthcare providers often do not have access to the necessary equipment, the training to 
use the equipment and respond appropriately to abnormal vital signs, nor access to effective 
referral pathways.4 It is in LMICs that women are dying from preventable complications of 
pre-eclampsia.  
 
The CRADLE Vital Signs Alert (VSA) is a hand-held, upper-arm, semi-automated device 
measuring BP and pulse to facilitate prompt recognition of abnormalities in vital signs. It has 
been designed specifically for healthcare providers from LMICs and meets the World Health 
Organisation’s requirements for use in low-resource settings.5 Device accuracy has been 
validated for use in pregnancy, including pre-eclampsia and low BP in pregnancy.6-8 The 
device incorporates a traffic light early warning system, aimed at alerting all healthcare 
providers (regardless of training) to vital sign abnormalities secondary to pre-eclampsia, 
maternal haemorrhage and sepsis. For pre-eclampsia, well-recognised thresholds for 
diagnosis have been selected for the thresholds triggering the lights (green = systolic BP < 
140 mmHg and DBP < 90 mmHg, yellow = systolic BP 140 – 159 and/or diastolic BP 90 – 109 
mmHg (but neither is above the upper threshold), red = systolic BP ≥ 160 mmHg and/or 
diastolic BP ≥ 110 mmHg).9  
 
Although clinicians rely on these recommended BP thresholds to guide diagnosis and 
management of pre-eclampsia, the thresholds that indicate increased risk of complications 
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of pre-eclampsia and (therefore dictate management) are based on expert opinion and 
limited data.9-14 This study aimed to determine whether recommended BP thresholds (that 
trigger yellow and red lights in the CRADLE VSA) are associated with adverse outcomes in 
women with pre-eclampsia at facility-level in South Africa. 
 
Methods 
This prospective observational cohort study was undertaken between January 2015 and May 
2016 at three state tertiary-level maternity units in South Africa (Groote Schuur, Tygerberg 
and Kimberley Hospitals). Women were eligible if they had a clinical diagnosis of pre-
eclampsia during their admission. There were no exclusion criteria.  
 
The study was approved by the Stellenbosch University Ethics Committee (N14/06068), 
University of Cape Town Ethics Committees (410/2014) and the University of the Free State 
Ethics Committee (230408-011). Local ethics committees at two of the three sites 
(Tygerberg Hospital and Kimberley Hospital) required individual informed written consent to 
be obtained before the woman was enrolled in the study (or waiver of consent was granted 
if the woman was unconscious). Institutional-level agreement for the study was given at the 
third site – Groote Schuur Hospital (i.e. individual-level consent was not required). 
 
All BP devices in the three maternity units, except those within the anaesthetic and recovery 
areas, were replaced by the CRADLE Vital Signs Alert (VSA). Management protocols were 
unaltered.  
 
BP on admission (‘admission BP’) and the highest BP during the course of the woman’s 
hospital stay (‘highest BP’) were recorded for each woman. Pre-specified adverse clinical 
outcomes were recorded and included maternal outcomes (death, eclampsia, stroke, kidney 
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injury), process measures (maternal use of magnesium sulfate, maternal Critical Care Unit 
(CCU) admission) and perinatal outcomes (extended perinatal death, delivery at <34 weeks 
and <37 weeks of gestation). Kidney injury was defined as highest creatinine during 
admission ≥90 μmol/L. Critical Care Unit admission was defined as admission to a critical 
care area providing at least additional monitoring and interventions.15 Extended perinatal 
death included stillbirth, early neonatal and late neonatal death.16 Data were extracted 
through patient notes reviewed by a local researcher and independently adjudicated. All 
women with pre-eclampsia were included but those with missing outcomes were excluded 
for that particular outcome analysis.  
 
The primary analysis was the relationship between clinical outcomes to the BP thresholds 
that trigger the CRADLE VSA traffic light early warning system, using non-parametric trend 
testing,17 odds ratios (with 95% confidence intervals) and post-test probability (with 95% 
confidence intervals) for outcomes. Post-test probability (defined as the proportion of 
women triggering each traffic light who have the outcome) and odds ratios for yellow 
compared to green and red compared to yellow traffic lights were calculated. The post-test 
probability was reported rather than sensitivity, specificity, and positive and negative 
predictive values related to a single threshold (as recommended by Sackett et al)18 and 95% 
confidence intervals were included to allow for generalisation from the sample to the 
population with similar characteristics. The clinical outcomes associated with ‘highest’ SBP 
was assessed using Area Under the Receiver Operator Characteristic Curve (AUROC). 
Absolute differences in outcomes at increasing ‘highest’ SBP was illustrated using line 
graphs. Stepwise logistic regression analysis explored possible inflection points of 
‘admission’ and ‘highest’ systolic and diastolic BP across the outcomes, including at the 
traffic light thresholds of SBP 140mmHg, SBP 160mmHg, DBP 90mmHg and DBP 110mmHg. 
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For perinatal outcomes, an adjustment for clustering was made, using semi-robust standard 
errors, to allow for the inclusion of multi-fetal pregnancies. 
A post-hoc power calculation for two principal outcomes (eclampsia and extended perinatal 
death) showed that the rate of eclampsia could be estimated to within 0.9% of the true 
value with 95% confidence and the rate of extended perinatal death could be estimated to 
within 1.3% of the true value with 95% confidence, based on incidence in previous 
literature.19 Statistical analysis was performed in the statistical package Stata (version 11.2), 
College Station, TX. The study is reported in accordance with STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) guidelines.  
 
Results 
A total of 1547 women with pre-eclampsia were eligible, consented and were included in 
the analysis, with 42 twin pregnancies (Figure 1). The number of women who declined to 
take part was not documented. Participant characteristics and BP results are shown in Table 
1.  511 (33.0%) women triggered a red light as their ‘admission’ BP and 1216 (78.6%) women 
triggered a red light at their ‘highest’ BP; nine (0.6%) women did not trigger a yellow or red 
light as an inpatient i.e. their BP remained within normal limits (their diagnosis of pre-
eclampsia was fulfilled by hypertension prior to admission).  
 
Table 2 shows the incidence of each outcome. Sixteen (1%) of the women died during their 
admission. Eclampsia occurred in 147 (9.5%) women and stroke occurred in 4 (0.3%) 
women. Analysis of characteristics of the four women with stroke was limited; however, 
mean ‘highest’ SBP was 188 mmHg (SD 33) and mean DBP at the time of ‘highest’ SBP was 
114 mmHg (SD 7.7).  
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Tables 3 and 4 show the non-parametric trend test, odds ratios and post-test probability for 
outcomes for ‘admission BP’ and ‘highest BP’ traffic lights triggered and associated 
outcomes. Odds ratios for ‘highest BP’ yellow versus green were not calculated as there 
were too few green lights triggered (n=9, 0.6% of ‘highest’ lights) for meaningful 
comparison, as expected in this high-risk cohort.  
 
For those triggering a red light compared to yellow light as their ‘admission’ BP, there was a 
significant increase in kidney injury, maternal use of magnesium sulfate and maternal CCU 
admission, but not for maternal death, eclampsia, extended perinatal death or preterm 
delivery (<34 or <37 weeks), which had a consistently high risk across yellow and red lights. 
Comparing ‘admission’ yellow and green lights, there was no significant difference in any of 
the outcomes. For those triggering a red compared to yellow light as their ‘highest’ BP, there 
was a significant increase in kidney injury, maternal use of magnesium sulfate, CCU 
admission and preterm delivery (<34 or <37 weeks); but not for maternal death, eclampsia 
or extended perinatal death.  
 
Figure 2 shows the association between ‘highest’ SBP and clinical outcomes, according to 
AUROC values (95% confidence intervals), and the association between increasing ‘highest’ 
SBP and absolute differences in outcomes. 
 
Stepwise logistic regression analysis showed that outcomes were consistently poor across 
the BP range. However, there was no consistent inflection point of either systolic or diastolic 
BP for ‘admission’ or ‘highest’ BP that demonstrated a change in outcomes; this included at 
the traffic light thresholds of SBP 140mmHg, SBP 160mmHg, DBP 90mmHg and DBP 
110mmHg. ‘Highest’ SBP ≥210 mmHg was associated with a significantly increased risk of 
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kidney injury, maternal CCU admission, pre-term delivery <34 weeks and stillbirth, but not 
other outcomes.  
 
 
 
Discussion 
Statement of principal findings 
The risk of maternal death, eclampsia, and perinatal death was similar across the women 
who triggered a yellow or red light on the CRADLE VSA. The risk of kidney injury, maternal 
use of magnesium sulfate, maternal CCU admission and preterm delivery, was greater for 
those who triggered a red light, compared to a yellow light.  
 
Strengths and weaknesses of the study 
Previous literature has focused on the association between pre-diagnosis BP and subsequent 
development of pre-eclampsia. This prospective observational study of a large multi-centre 
cohort of pre-eclamptic women assessed the association between CRADLE VSA BP 
thresholds (at and during admission) and pre-eclampsia complications.  
 
This study ensured the use of accurate BP devices, validated for use in pregnancy including 
pre-eclampsia, for BP measurement in a pre-eclamptic cohort (rare in previous literature). 
This is important because the majority of commercially available automated BP devices have 
not been validated for use in pregnancy including pre-eclampsia and consistently 
underestimate BP in women with pre-eclampsia.20 The use of non-validated BP devices for 
clinical studies involving pre-eclamptic women raises the question of accuracy of the “test” 
in these studies and possible underestimation of true BP. In this study, the association 
between accurate BP values and complications of pre-eclampsia was explored.  
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It was not feasible to collect reliable data on choice and timing of antihypertensive, timing of 
magnesium sulfate administration and timing of eclampsia and stroke in relation to delivery, 
due to lack of systematic documentation in this setting. It was not possible to determine 
timing of stillbirth; often diagnosis was made at admission but could have occurred prior to 
admission. Therefore, assessing associations with antihypertensive use, temporal trends, 
and comparisons between antepartum and postpartum eclampsia was not possible. For 
example, it was possible for eclampsia and peripheral clinic antihypertensive and 
magnesium sulfate administration to have taken place prior to hospital admission. This may, 
in part, explain why the BP thresholds were not strongly associated with some outcomes, 
including eclampsia.  
 
The clinicians were using the BP devices provided by the study as part of routine practice 
and were not blinded to the BP readings. The decision to use magnesium sulfate and admit 
to maternal CCU may well have been in response to BP readings. Each study site followed 
similar departmental guidelines for the management of pre-eclampsia. Guidelines included 
the recommendation that magnesium sulphate should be administered in women with pre-
eclampsia with severe hypertension (systolic BP ≥160mmHg and/or diastolic BP≥110mmHg) 
or in symptomatic pre-eclampsia without severe hypertension. Those requiring magnesium 
sulphate may have also been managed in CCU. The association between red traffic light and 
increasing ‘highest’ SBP and these process measures reflects appropriate response to severe 
hypertension, but may limit their use as independent outcomes.  
 
At one of the sites (Kimberley Hospital), the proportion of women admitted to CCU was 
higher than at the other two sites. This can be explained by the criteria at which CCU 
admission was mandated at that site; Kimberley Hospital had a lower threshold for CCU 
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admission, which tended to care for less severely unwell patients than the other two sites. 
The relationship between severity of hypertension and CCU admission exists despite this 
variation between sites. 
 
Strengths and weaknesses in relation to other studies 
National and international guideline BP thresholds recommendations are not robustly 
evidence-based.9, 11-14, 21 A recent prospective multicentre study of 2023 pre-eclamptic 
women demonstrated a relationship between both SBP and DBP and adverse outcome. 
However specific thresholds of BP were not evaluated and adverse outcomes in this high-
income setting were far lower than in our cohort.22 A similar prospective study of 2081 
hypertensive women from five LMICs demonstrated a relationship between SBP and a 
composite adverse maternal outcome.23 Although in a more comparable cohort of women 
and with similar aims to our study, again thresholds of BP were not evaluated.  
 
Meaning of study – Explanations 
Women triggering a red traffic light at some point during their admission had a higher risk of 
kidney injury, preterm delivery and process measure outcomes. These outcomes may have 
been a consequence of the uncontrolled hypertension and subsequent decisions to 
intervene (i.e. to deliver the baby) and may not be independent of the severity of 
hypertension. It was not possible to distinguish between acute kidney injury as a 
consequence of pre-eclampsia and hypertension as a consequence of chronic renal disease, 
as baseline creatinine levels were not known. Kidney injury is usually an acute complication 
in women in low-income countries.24 This is common to many pregnancy populations where 
women will not have had a baseline creatinine measured.  
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A red light did not confer additional risk for maternal death, eclampsia, stillbirth and 
neonatal death. These findings are consistent with a Haitain pre-eclampsia cohort 
demonstrating ‘highest’ SBP and DBP during admission were not associated with additional 
risk of maternal death, eclampsia or antepartum stillbirth.25 The poor relationship between 
eclampsia and increasing ‘highest’ SBP mirror findings from a secondary analysis study of 87 
women with eclampsia and neuroimaging findings of posterior reversible leuco-
encephalopathy syndrome, which showed that more than a third of women had BPs within 
normal limits (<140/90 mmHg) prior to their eclampsia.26 A prospective observational study 
of all eclampsia cases in the UK in 1992 demonstrated that only 38% of in-hospital eclampsia 
cases were associated with documented proteinuria or hypertension prior to the fit.27 In our 
study, risk of eclampsia does not have a close relationship with severity of hypertension. It is 
possible that eclampsia may occur at moments of acute severe hypertension, which may not 
always be captured.  
 
In non-pregnant populations, there is a strong association between increasing systolic BP 
and risk of stroke.28-30 The association between stroke risk and severe systolic hypertension 
is not robust in obstetric populations. In 2005, in 28 women with sustained pre-eclampsia-
related strokes, all had a SBP ≥155mmHg just prior to the stroke.31 In our data systolic BPs 
above this threshold were common, yet strokes were rare (despite the four women with 
strokes also having severe hypertension). This may reflect appropriate and timely 
management with antihypertensives, magnesium sulphate, CCU admission and delivery of 
the baby in response to severe hypertension. In lower-resourced settings, the association 
between severe hypertension and adverse outcomes may be stronger.  
 
Meaning of study - Implications for clinicians/policy 
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This study aimed to inform whether the BP thresholds incorporated in the CRADLE VSA 
traffic light early warning system are appropriate as triage tools for healthcare providers 
caring for pregnant women in low-resource community settings. The study demonstrated 
that pre-eclamptic women who trigger a yellow or red traffic light are at increased risk of 
complications of pre-eclampsia, but not for all outcomes. Although the relationship between 
severity of hypertension and risk of some adverse outcomes, such as eclampsia and stroke, 
was not strong, these findings should not deter from accurate BP measurement and timely 
intervention. As discussed above, in the tertiary care setting, treatment paradox and 
temporal influences may have impacted on the strength of the association.  
 
In a community setting, accurate BP measurement is a critical screening test. In this 
unselected population, the CRADLE VSA’s yellow light will identify women who are 
hypertensive (possibly due to pre-eclampsia), at increased risk of a number of pre-eclampsia 
complications, and who need urgent referral to facility-level care. This should be more 
urgent when a red light is triggered. The traffic light early warning system enables 
healthcare providers with limited training to do this without requiring literacy.  
 
Unanswered questions and future research 
The traffic light early warning system within the CRADLE VSA device alerts healthcare 
providers to hypertension and also to shock secondary to obstetric haemorrhage or sepsis. A 
concurrent study at the same three South African sites evaluated whether thresholds of 
shock index (the ratio of pulse to SBP)32 can predict adverse outcomes relating to obstetric 
haemorrhage and sepsis. Following these two studies, we will assess whether 
implementation of the CRADLE VSA and a simple training package to healthcare providers 
caring for pregnant women in low-resource community- and facility-level settings improves 
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outcomes for women (CRADLE 3 Trial), by improving the identification of the three leading 
causes of maternal death (pre-eclampsia, obstetric haemorrhage and sepsis). 
  
  
Figure 1. Flow diagram of participants  
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Table 1. Mean ± standard deviation or number (percentage) of demographic, admission and delivery 
characteristics 
 
All sites 
Groote Schuur 
Hospital 
Kimberley 
Hospital 
Tygerberg 
Hospital 
Number of women 
1547 770 (49.8) 167 (10.8) 610 (39.4) 
DEMOGRAPHICS     
Age at delivery, year 27.6±6.2 28.0±6.0 28.3±7.2 27.0±6.2 
Body mass index, kg/m
2
 30.4±7.73 31.0±8.3 31.9±8.3 29.2±6.7 
Multiparous 983 (63.5) 514 (66.8) 117 (70.1) 352 (57.7) 
ADMISSION     
Gestation on admission, weeks 32.8±4.9 32.0±4.8 33.9±4.7 33.5±4.9 
Systolic BP 150±20.6 150±22.3 147±20.0 150±18.2 
Diastolic BP  97±15.4 98±15.6 92±16.9 97±14.3 
‘Admission’ light     
Green 271 (17.5) 136 (17.7) 42 (25.2) 93 (15.3) 
Yellow 765 (49.5) 361 (46.9) 85 (50.9) 319 (52.3) 
Red 511 (33.0) 273 (35.5) 40 (24.0) 198 (32.5) 
Admission dipstick proteinuria     
Negative/Trace 165 (10.7) 93 (12.1) 69 (42.6) 3 (0.5) 
+1 196 (12.7) 134 (17.4) 15 (9.3) 47 (7.7) 
+2 578 (37.5) 245 (31.9) 32 (19.8) 301 (49.3) 
+3 601 (39.0) 296 (38.5) 46 (28.4) 259 (42.5) 
DELIVERY     
Gestation at delivery, weeks 33.4±4.7 32.8±4.5 34.5±4.4 33.9±4.9 
Induction or pre-labour Caesarean section 1357 (87.8) 636 (82.6) 147 (88.6) 574 (94.3) 
Caesarean section (pre-labour and emergency) 1060 (69.7) 549 (71.3) 115 (69.3) 417 (68.5) 
‘Highest’ BP (mmHg):     
Systolic BP 172±16.9 174±17.9 171±16.1 170±15.7 
Diastolic BP  104±14.60 106±15.7 102±17.1 103±12.2 
‘Highest’ light during admission      
Green 9 (0.6) 5 (0.6) 0 (0) 4 (0.7) 
Yellow 322 (20.8) 139 (18.1) 42 (25.1) 141 (23.1) 
Red 1216 (78.6) 626 (81.3) 125 (74.9) 465 (76.2) 
Diastolic BP indicates diastolic blood pressure at the time of ‘highest’ systolic BP; ‘highest’ light during 
admission indicates the light triggered at the time of ‘highest’ systolic BP. 
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Table 2. Number (percentage) of maternal, perinatal and process measure outcomes 
 
All sites 
Groote 
Schuur 
Hospital 
Kimberley 
Hospital 
Tygerberg 
Hospital 
Number of women 1547 770 (49.8) 167 (10.8) 610 (39.4) 
MATERNAL OUTCOMES     
Maternal death 16 (1.0) 3 (0.4) 6 (3.6) 7 (1.1) 
Eclampsia (at any time) 147 (9.5) 71 (9.2) 16 (9.6) 60 (9.8) 
Stroke (at any time) 4 (0.3) 2 (0.3) 0 (0) 2 (0.3) 
Kidney injury  272 (17.6) 174 (22.6) 21 (14.0) 72 (11.8) 
SECONDARY OUTCOMES     
PROCESS MEASURES     
Maternal magnesium sulfate 1345 (86.9) 686 (89.1) 120 (71.9) 539 (88.4) 
Maternal Critical Care Unit 
admission 
453 (29.3) 105 (13.6) 114 (68.3) 234 (38.4) 
Total number of infants 1589 793 172 624 
PERINATAL OUTCOMES     
Stillbirth 281 (17.7) 162 (20.4) 16 (9.3) 103 (16.5) 
Early neonatal death 39 (2.5) 21 (2.6) 6 (3.5) 12 (1.9) 
Late neonatal death 12 (0.8) 5 (0.6) 4 (2.3) 3 (0.5) 
Preterm birth <34 weeks 544 (41.7) 303 (48.2) 52 (33.3) 189 (36.3) 
Preterm birth <37 weeks 913 (70.0) 491 (78.1) 99 (63.5) 323 (62.1) 
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Table 3. Frequency, post-test probability for outcomes (95% CI) of outcomes across green, yellow and red ‘admission’ traffic light thresholds, odds ratios (95% CI) of yellow 
vs. green and red vs. yellow traffic lights and non-parametric trend test for worsening traffic light triggers (green to yellow to red). 
Outcomes  Maternal 
death 
Eclampsia Kidney injury Magnesium 
sulfate use 
CCU admission Extended 
perinatal death 
Delivery <34 
weeks 
Delivery <37 
weeks 
Post-test 
probability for 
outcomes (n, %, 
95% CI) 
        
Green  3/271 
1.1 (0.2, 3.2) 
26/271 
9.6 (6.4, 13.7) 
44/271 
16.3 (12.1, 21.3) 
228/271 
84.1 (79.2, 88.3) 
67/271 
24.7 (19.7, 30.3) 
62/279 
22.2 (17.2, 27.2) 
96/224 
42.9 (36.2, 49.5) 
158/224 
70.5 (64.4, 76.6) 
Yellow  7/765 
0.9 (0.4, 1.9) 
65/765 
8.5 (6.6, 10.7) 
111/765 
14.6 (12.1, 17.3) 
635/765 
83.0 (80.2, 85.6) 
205/765 
26.8 (23.7, 30.1) 
166/784 
21.2 (18.3, 24.1) 
250/642 
38.9 (35.1, 42.8) 
451/642 
70.2 (66.7, 73.8) 
Red  6/511 
1.2 (0.4, 2.5) 
56/511 
11.0 (8.4, 14.0)   
117/511 
22.9 (19.3, 26.8)   
482/511  
94.3 (92.0, 96.2)  
181/511 
35.4 (31.3, 39.7)   
104/526  
19.8 (16.3, 23.2)  
200/442 
45.2 (40.4, 50.1)   
307/442 
69.5 (65.0, 73.9)   
Yellow vs green  
OR (95% CI) 
0.82 
(0.21, 3.21) 
0.88 
(0.54, 1.41) 
0.87 
(0.60, 1.28) 
0.92 
(0.63, 1.34) 
1.11 
(0.81, 1.543 
0.94 
(0.68, 1.31) 
0.85 
(0.62, 1.16) 
0.99 
(0.71, 1.38) 
Red vs yellow 
OR (95% CI) 
1.29 
(0.43, 3.85) 
1.32 
(0.91, 1.93) 
1.74 
(1.31, 2.33) 
3.40 
(2.24, 5.18) 
1.50   
(1.18, 1.91) 
0.92 
(0.70, 1.21) 
1.30 
(1.01, 1.66) 
0.96 
(0.74, 1.25) 
P† 0.851 0.369 0.003 <0.001 <0.001 0.394 0.294 0.750 
Values in bold indicate statistical significance.  
CCU, Critical Care Unit; CI, confidence interval; OR, odds ratio. 
*not calculable due to 0% or 100%; †All P values are based on the non-parametric test for trend 
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Table 4. Frequency, post-test probability for outcomes (95% CI) of outcomes across green, yellow and red ‘highest’ traffic light thresholds, odds ratios (95% CI) of yellow vs. 
green and red vs. yellow traffic lights and non-parametric trend test for worsening traffic light triggers (green to yellow to red).  
Outcomes  Maternal 
death 
Eclampsia Kidney injury Maternal 
magnesium 
sulfate 
Maternal CCU 
admission 
Extended 
perinatal death 
Delivery <34 
weeks 
Delivery <37 
weeks 
Post-test 
probability for 
outcomes (n, %, 
95% CI) 
        
Yellow  2/322 
0.6 (0.1, 2.2) 
25/322 
7.8 (5.1, 11.2) 
28/322 
8.72 (5.9, 12.4) 
246/322 
76.4 (71.4, 80.9) 
68/322 
21.1 (16.8, 26.0) 
69/33 
20.7 (16.3, 
25.1) 
85/268 
31.7 (26.0, 
37.5) 
164/268 
61.2 (55.2, 
67.2) 
Red  14/1216 
1.2 (0.6, 1.9) 
122/1216 
10.0 (8.4, 11.9) 
243/1216 
20.0 (17.8, 22.4) 
1093/1216 
89.9 (88.1, 91.5) 
385/1216 
31.7 (29.1, 34.4) 
258/1247 
20.7 (18.4, 
23.0) 
460/1036 
44.4 (41.3, 
47.5) 
750/1036 
72.4 (69.6, 
75.2) 
Red vs yellow 
OR (95% CI) 
1.86 (0.42, 
8.24) 
1.32 (0.85, 2.08) 2.62 (1.73, 3.96) 2.75 (2.00, 3.77) 1.73 (1.29, 2.32) 1.00 (0.74, 
1.35) 
1.72 (1.29, 
2.29) 
1.66 (1.26, 
2.20) 
P† 0.373 0.139 <0.001 <0.001 <0.001 0.415 <0.001 <0.001 
Values in bold indicate statistical significance.  
CCU, Critical Care Unit; CI, confidence interval; OR, odds ratio. 
*not calculable due to 0% or 100%; †All P values are based on the non-parametric test for trend  
  
Figure 2. Absolute difference in maternal outcomes (panel A), process outcomes (panel B), perinatal 
outcomes (panel C) at increasing systolic BP (‘highest’ during admission) from 140 mmHg and the area 
under the receiver operating characteristic curve (AUROC) values for the performance of highest SBP 
to predict outcomes, with incidence (%) of outcomes shown below.  
Panel A 
 
Incidence (%) 140-149 150-159 160-169 170-179 180-189 190-199 ≥200 
Kidney Injury 
(n=272) 
6.0 9.6 15.1 15.8 22.8 29.0 41.6 
Eclampsia 
(n=147) 
6.0 9.2 8.5 8.8 12.5 9.7 14.6 
Maternal death 
(n=16) 
3.6 0.4 0.5 1.5 0 1.6 3.4 
 
  
  
Panel B 
 
Incidence (%) 140-149 150-159 160-169 170-179 180-189 190-199 ≥200 
CCU admission 
(n=453) 
17.9 23.8 17.4 30.6 37.1 44.4 61.8 
Magnesium 
sulfate use 
(n=1345) 
67.9 80.8 84.8 88.5 94.4 96.8 97.8 
 
 
 
 
 
 
 
 
 
 
  
 
Panel C 
 
Incidence (%) 140-149 150-159 160-169 170-179 180-189 190-199 ≥200 
Delivery <34 weeks 
(n=544) 
21.7 37.0 38.2 46.8 43.3 51.2 58.2 
Delivery <37 weeks 
(n=913) 
46.4 64.9 71.6 71.5 72.7 74.8 74.6 
Stillbirth 
(n=281) 
17.9 19.2 13.8 19.1 19.4 16.9 24.7 
Neonatal death 
(n=51) 
1.5 1.4 2.8 6.0 4.3 8.7 6.0 
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Highlights 
 
• The CRADLE Vital Signs Alert is designed to risk stratify women with pre-
eclampsia 
• A yellow or red light corresponds to increased risk of pre-eclampsia 
complications 
• Those who trigger a yellow or red light need escalation of care 
 
